A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

Amy Jo Chien,Amelia S Gliwa,Siti Rahmaputri,Heidi F Dittrich,Melanie Catherine Majure,Hope S. Rugo,Michelle E. Melisko,Pamela N. Munster,John W. Park,Mark M. Moasser,Mehrdad Matloubian,Tasha Lea,Julia Rohrberg,Gregor Krings,Andrei Goga

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

2020

Amy Jo Chien
Amelia S Gliwa
Siti Rahmaputri
Heidi F Dittrich
Melanie Catherine Majure
Hope S. Rugo
Michelle E. Melisko
Pamela N. Munster
John W. Park
Mark M. Moasser
Mehrdad Matloubian
Tasha Lea
Julia Rohrberg
Gregor Krings
Andrei Goga

1076Background: Increased expression of the MYC transcriptional oncogene is found in about 70% of TNBC and is associated with poor prognosis. In MYC-overexpressing TN xenografts, CDK1 inhibition wi...

Keywords:

Triple-negative breast cancer
Cancer research
Pembrolizumab
Cyclin-dependent kinase
Dinaciclib
Medicine
in patient
Pathology
Cyclin-dependent kinase 1
Oncogene
poor prognosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations